Image: The Multiplo Complete (TP/nTP) Syphilis Antibody Test has received CE Mark (Photo courtesy of MedMira Inc.)
–
Syphilis is a sexually transmitted disease that has a major impact on global health. In 2018 alone, the European CDC reported 34,000 new confirmed cases of syphilis with a 70% increase in the reporting rate in 2017 compared to 2010. They also found that, for the first time since the early 2000s, countries of the EU/EEA reported more cases of syphilis than HIV. Since there are treatments to prevent the progression of syphilis, rapid diagnosis and treatment of infected persons along with rapid identification of sexual contacts is of high priority. Now, the only commercially available combined screening and confirmation test for syphilis takes less than three minutes (from sample collection to easy-to-read results) for diagnosis at the POC.
The Multiplo Complete Syphilis Antibody (TP/nTP) Test (Multiplo TP/nTP) from MedMira Inc. (Halifax, Canada) uses its unique RVF technology to combine the detection of treponemal (TP) and non-treponemal (nTP) antibodies. ) in a test. The test targets biomarkers indicative of active and prior infections, thereby providing a comprehensive approach that combines the detection and confirmation steps employed in testing strategies globally.
Unlike traditional syphilis testing options, the new robust and easy-to-use diagnostic solution is MedMira’s answer to the growing demand for flexible, accurate and cost-effective syphilis testing. Multiplo TP/nTP not only identifies TP exposure, but can also determine acute infection status through non-treponemal screening and treponemal confirmatory testing. This allows a complete diagnosis of syphilis in a single device. MedMira has received the CE mark for its Multiplo TP/nTP test which allows the company to offer the test in all markets that accept the CE mark.
“MedMira received CE Mark in March 2022 for its Reveal TP (Syphilis) Antibody Test (Reveal TP) intended to diagnose potential acute syphilis infections. The product is specifically designed for hospitals and healthcare providers that have an existing screening setup like VDRL or RPR but require a rapid confirmatory test like our Reveal TP. MedMira’s Multiplo TP/nTP, on the other hand, will provide a complete system that combines detection and confirmation in a single test. This product is designed for customers who do not have immediate access to VDRL or RPR, such as physician offices, pharmacies, and home testing users,” said Hermes Chan, CEO of MedMira. “Our Multiplo TP/nTP further enhances our comprehensive product offering for our distribution partners and customers by providing a clear answer within minutes at the lowest possible cost. At the same time, MedMira brand recognition is increasing in the sexually transmitted disease market.”
Related links:
MedMira Inc.
–
